



NEWS RELEASE

Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

3/12/2024

AUSTIN, Texas--(BUSINESS WIRE)-- **Natera, Inc.** (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024.

A total of seven abstracts will be presented, including two oral presentations and five poster presentations. The presentations will feature new data highlighting Signatera’s predictive and prognostic utility in ovarian cancer and other gynecologic malignancies.

“On the heels of receiving Medicare coverage for Signatera in ovarian cancer and for breast cancer in the neoadjuvant setting, we are thrilled to share new Signatera and Empower data with the gynecologic oncology community,” said Adam ElNaggar, MD, medical director of oncology at Natera. “We believe this momentum is indicative of the growing clinical value our tests provide for patients across the continuum of gynecologic cancer care, and demonstrate our continued leadership in MRD.”

Below is the full list of Signatera and Empower data presentations at the SGO Annual Meeting.

Oral Presentations:



- Focused Plenary I: The Science to Drive Purpose | March 16, 2:15 - 3:30 PM | Presenter: Anne Knisely, MD | Ovarian Cancer

Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA (ctDNA) in patients with ovarian cancer after frontline therapy

- Focused Plenary IV: ctDNA: Molecular Mirrors & Markers | March 17, 1:45 - 2:45 PM | Presenter: Mike Shalamov | Gynecologic Cancers

Utility of ctDNA as an early predictive biomarker of response to radiation in gynecologic malignancies

Poster Presentations:

- Poster #1241 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Michael Toboni, MD | Ovarian Cancer

PARPi response monitoring using personalized ctDNA testing in patients with ovarian cancer

- Poster #1242 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Peter W. Ketch, MD | Uterine Cancer

Treatment Monitoring Utilizing ctDNA-based MRD Detection in Early Stage Uterine Cancer

- Poster #1243 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Michael Toboni, MD | Uterine Cancer

Personalized ctDNA analysis used for ctDNA detection and response monitoring in patients with advanced or recurrent uterine cancer

- Poster #1274 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Floortje Backes, MD | Endometrial and Ovarian Cancer

Utility of ctDNA in assessment of treatment response in patients with Recurrent/Metastatic Endometrial Cancer and Recurrent/Platinum-Resistant Ovarian Cancer

- Poster #1181 | Session 1 | March 17, 1:15 - 2:45 PM | Presenter: Sarah Lee, MD | Pan-cancer

Diagnostic yield and characteristics of germline-positive genetic testing ordered by obstetricians and gynecologists in female patients with a personal history of cancer

About Signatera

Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with



cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer and muscle invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 50 peer-reviewed papers.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Investor Relations:

Mike Brophy, CFO

Natera, Inc.

510-826-2350

investor@natera.com

Media:

Lesley Bogdanow, VP of Corporate Communications

Natera, Inc.

pr@natera.com

Source: Natera, Inc.